CClinicalTrials.gg
Not yet recruitingNCT07600047Updated Sep 29, 2026

A Well-Being Intervention for People With IBS

An interventional study of Well-Being Intervention in Irritable Bowel Syndrome, sponsored by University of Wisconsin, Madison. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this randomized behavioral clinical trial is to examine whether a well-being intervention can improve both psychological well-being and physical outcomes in adults with Irritable Bowel Syndrome (IBS). The study aims to assess whether this intervention decreases anger, anxiety, and depression; increases self-esteem, empathy, and hope; and improves quality of life indicators such as IBS symptom severity, sleep quality, fatigue, and diet. Participants can expect to be on study for up to 9 months.

Read the detailed description

This study consists of two phases:

Study 1 (Screening and Baseline Assessment):

Participants who self-identify as having been diagnosed with IBS and receive care at the University of Wisconsin (UW) Digestive Health Center will complete a battery of self-report questionnaires assessing well-being, anger, anxiety, depression, self-esteem, empathy, hope, sleep quality, fatigue, diet, and IBS symptom severity.

Study 2 (Intervention Phase - registered here):

Eligible participants will be randomized to either an experimental well-being intervention or a waitlist control condition. Participants assigned to the waitlist control condition will not receive the intervention during the initial intervention period but will complete all scheduled assessments. After completion of the first post-test assessment, waitlist participants will receive the same 15-session well-being intervention (crossover design).

The intervention will be held once a week for 15 weeks, lasting approximately one hour per session, conducted in a private meeting room at the Digestive Health Center. Sessions focus on emotional awareness, perspective-taking, and developing the capacity to overcome hurt and resentment toward a person who acted unfairly.

Following completion, both groups will complete post-test and follow-up assessments identical to the baseline questionnaires. Qualitative interviews will be conducted to explore participants' experiences with the intervention.

[Note - so as not to bias participants, specific information about the intervention will be withheld until the study is complete]

02

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • well being
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Men and women currently diagnosed with Irritable Bowel Syndrome (IBS) by a healthcare provider.
  • Able to read and write in English.
  • Willing to complete questionnaires and participate in either the intervention or control group.
  • Capable of providing informed consent.
  • Must be a UW Health patient or referred through UW Digestive Health Center.

Exclusion criteria

Exclusion Criteria:

  • Individuals with cognitive impairments or reading difficulties that would interfere with understanding study materials or completing assessments.
  • Individuals unable to provide informed consent.
  • Prior participation in a similar intervention study.
  • Non-English speakers (since study materials are in English)
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Well-Being Intervention

    Behavioral: Well-Being Intervention

  • Active comparator
    Waitlist Control (delayed Well-Being Intervention)

    Behavioral: Well-Being Intervention

Interventions

  • BehavioralWell-Being Intervention

    The intervention will be once weekly over a 15-week period, lasting approximately one hour per session.

05

What researchers measure

Primary outcomes

  1. Anger measured by PROMIS Anger Scale Score

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Anger Scale is scored from 5-25 where higher scores indicates more anger.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  2. Anxiety measured by PROMIS Anxiety Scale Score

    The PROMIS Anxiety Scale is scored from 7-35 where higher scores indicates more anxiety.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  3. Depression measured by IBS PROMIS Depression Scale Score

    The IBS PROMIS Depression Scale is scored from 8-40 where higher scores indicates more depression.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  4. Fatigue measured by IBS Fatigue 8a Score

    The IBS Fatigue 8a Scale is scored from 8-40 where higher scores indicates more fatigue.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  5. Sleep Disturbance measured by IBS Sleep Disturbance 8b

    The IBS Sleep Disturbance 8b Scale is scored from 8-40 where higher scores indicates more sleep disturbance.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  6. Pain measured by Item 1b of the IBS Symptom Severity Scale

    This item is scored from 0-100 where higher scores indicates increased pain.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  7. IBS Severity Score measured by IBS Symptom Severity Scale

    The IBS Symptom Severity Scale is scored from 0-100 where higher scores indicates more severe IBS symptoms.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  8. Well-Being measured by a 30 item Inventory

    The inventory is scored from 30-180 where higher scores indicates greater level of well-being.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  9. Self-esteem measured by Rosenberg Self Esteem Scale Score

    The Rosenberg Self Esteem Scale is scored from 0-30 where higher scores indicates higher self esteem.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  10. Empathy measured by Empathy Questionnaire

    The Empathy Questionnaire is scored from 0-64 where higher scores indicates higher empathy.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  11. Hope measured by Heart Hope Index Score

    The Heart Hope Index is scored from 12-48 where higher scores indicates greater hope.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

  12. Healthy Diet Pattern measured by an IBS Diet Survey

    The Diet Survey is scored from 5-24 where higher scores indicate healthier diet pattern.

    Time frame: Data will be collected up to 17 weeks and will include a 4-and 12-week post-intervention assessment for both the waitlist-control and intervention groups (intervention group up to 29 weeks on study and the waitlist-control group up to 46 weeks on study)

06

Study locations

1 site
  • UW Health Digestive Health Center
    Madison, Wisconsin 53705, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07600047
Lead sponsor
University of Wisconsin, Madison
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Dec 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Mark Benson, MD
Contact
mb4@medicine.wisc.edu
608-263-1995
Mark Benson, MD
principal investigator · UW School of Medicine and Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion